Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Biodesix, Inc.NASDAQ: BDSX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$7.79M, compared with -$11.1M a year earlier. Trailing-twelve-month income before tax was -$31.96M.

Context

  • Income before tax amounted to 39.8% of revenue in FY2025, down 20.3 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$7.79M or moves back toward the trailing-twelve-month quarterly average of -$7.99M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.79M-95.8% QoQ
Last fiscal yearDec 2025
-$35.27M+17.9% YoY
LTMMar 2026
-$31.96M+20.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.8%——
1 year+17.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(35.27M) USD
Year-over-year change
+17.9%

Income Before Tax vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 income before tax of -$31.96M is the 2nd highest of the 5 companies compared; the peer median is -$37.48M.
  • Its year-over-year change of +20.9% is the 2nd highest of 5, against a peer median of +13.0%.
  • Income before tax amounts to 33.3% of revenue for BDSX, versus a peer median of 58.5%.
BDSX Competitors Peer median
Income Before Tax for BDSX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026-$31.3M +42.4%—58.5%
BDSXBiodesix, Inc.LTM Mar 2026-$31.96M +20.9%—33.3%
PDSBPDS Biotechnology CorporationLTM Mar 2026-$33.36M +11.1%——
INMBINmune Bio, Inc.LTM Mar 2026-$41.6M -2.0%——
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$58.75M +14.8%——
Peer median (excluding BDSX) -$37.48M+13.0%—58.5%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue54.51M38.21M49.09M71.32M88.5M
Cost of Revenue30.52M14.15M13.01M15.57M16.72M
Gross Profit23.99M24.06M36.08M55.75M71.78M
Gross Margin44.0%63.0%73.5%78.2%81.1%
Research & Development12.79M13.1M9.99M9.56M12M
Selling, General & Admin50.52M61.46M67.39M80.45M87.55M
Operating Expenses64.93M74.65M77.42M90.25M99.55M
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
EBITDA(35.47M)(51.53M)(37.1M)(29.22M)(21.95M)
EBITDA Margin-65.1%-134.9%-75.6%-41.0%-24.8%
Operating Income(40.94M)(50.59M)(41.34M)(34.5M)(27.77M)
Operating Margin-75.1%-132.4%-84.2%-48.4%-31.4%
Interest Income00000
Interest Expense4.51M8.07M9.54M8.26M7.72M
Other Income / Expenses(2.22M)(14.86M)(10.8M)(8.43M)(7.5M)
Income Before Tax(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Pre-Tax Margin-79.2%-171.3%-106.2%-60.2%-39.8%
Income Tax Expense00000
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Net Margin-79.2%-171.3%-106.2%-60.2%-39.8%
EPS (Basic)(31.60)(31.00)(12.80)(6.60)(4.67)
EPS (Diluted)(31.60)(31.00)(12.80)(6.60)(4.67)
Weighted Avg Shares1.37M2.11M4.11M6.48M7.55M
Weighted Avg Shares (Diluted)1.37M2.11M4.11M6.48M7.55M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.